Protagonist Therapeutics, Inc. Share Price & Technical Analysis
PTGX · $99.98 (+0.80%)
Healthcare / Biotechnology
$99.98
+0.80%
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in P…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
0% return in May, 11% avg return in past 3 year May month.
15% return in 2026, 79% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 13% | 14% | -6% | 0% | – | – | – | – | – | – | – | 15% |
| 25 | -3% | 1% | 19% | -5% | 5% | 15% | -3% | 9% | 12% | 19% | 15% | -3% | 82% |
| 24 | 9% | 14% | -6% | -13% | 12% | 22% | 7% | 15% | 6% | 2% | -5% | -10% | 53% |
| 23 | 21% | 22% | 42% | -2% | 15% | 7% | -27% | 3% | -16% | -14% | 26% | 27% | 102% |
| 22 | -14% | -19% | -2% | -62% | -3% | -11% | 25% | -12% | -2% | -11% | -4% | 38% | -78% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Neutral
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.45B
P/E ratio
—
52W high
$107.8
52W low
$45.28
Volume
3,41,929
Beta
1.88
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Protagonist Therapeutics, Inc. share price today?
- Protagonist Therapeutics, Inc. (PTGX) last traded around $99.98 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PTGX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PTGX. Download the app for real-time alerts.
- How can I analyze Protagonist Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.